Navigate Up

UPMC/University of Pittsburgh Schools of the Health Sciences
For Journalists
Senior Manager
Telephone: 412-578-9193 or 412-624-3212
Manager
Telephone: 412-586-9776
Patient & Other Inquiries


New Study Will Test if Anti-Amyloid Antibody Can Prevent Development of Alzheimer’s Disease

 
PITTSBURGH, April 20, 2014 – Researchers at the University of Pittsburgh School of Medicine will be part of a multicenter trial that will test for the first time whether a drug that treats brain plaques can prevent later development of memory loss in Alzheimer’s Disease.
 
Studies have shown that brain changes in Alzheimer’s begin many years before disease onset, and that all patients have deposits of beta amyloid in their brains, said Oscar Lopez, M.D., professor of neurology, Pitt School of Medicine, and co-director of the Alzheimer’s Disease Research Center (ADRC). He is the principal investigator of the Pittsburgh arm of the Anti-Amyloid Treatment in Asymptomatic Alzheimer’s (A4) study.
 
“This is the first study to assess whether an experimental antibody that counteracts amyloid will have long-term impact that can prevent Alzheimer’s,” said Dr. Lopez, who noted that many people have beta amyloid deposits in the brain but never develop dementia. “We suspect that these plaques have a role in disease development, but it’s not been proven that they affect memory and cognition. The A4 study could shed light on that.”
 
For A4, the researchers will perform a baseline PET scan on otherwise healthy volunteers, ages 65 to 85, to determine if brain plaques are present. If so, participants will be randomly assigned to receive monthly intravenous infusions of the experimental anti-amyloid antibody or a placebo. All participants will have regular assessments and blood tests for three years.
 
“Because of the nature of the disease, a friend or family member also must be willing to answer questions annually about how the participant is doing at home,” Dr. Lopez explained. “This study could help us find ways of predicting who might be at greater risk for progressing to Alzheimer’s.”
 
People who are interested in participating should call study coordinator Katy Orchowski Zorich at 412-624-2730 or email her at orchowskik3@upmc.edu.

UPMC | Affiliated with the University of Pittsburgh Schools of the Health Sciences Supplemental content provided by Healthwise, Incorporated. To learn more, visit www.healthwise.org

For help in finding a doctor or health service that suits your needs, call the UPMC Referral Service at 412-647-UPMC (8762) or 1-800-533-UPMC (8762). Select option 1.

UPMC is an equal opportunity employer. UPMC policy prohibits discrimination or harassment on the basis of race, color, religion, ancestry, national origin, age, sex, genetics, sexual orientation, gender identity, marital status, familial status, disability, veteran status, or any other legally protected group status. Further, UPMC will continue to support and promote equal employment opportunity, human dignity, and racial, ethnic, and cultural diversity. This policy applies to admissions, employment, and access to and treatment in UPMC programs and activities. This commitment is made by UPMC in accordance with federal, state, and/or local laws and regulations.

Medical information made available on UPMC.com is not intended to be used as a substitute for professional medical advice, diagnosis, or treatment. You should not rely entirely on this information for your health care needs. Ask your own doctor or health care provider any specific medical questions that you have. Further, UPMC.com is not a tool to be used in the case of an emergency. If an emergency arises, you should seek appropriate emergency medical services.

UPMC
Pittsburgh, PA, USA | UPMC.com